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Eighteen Enterobacteriaceae and Pseudomonas aeruginosa strains, 16 of them with well-defined -lactam re
sistance mechanisms, were sent to 52 Spanish microbiology laboratories. Interpretative categories for 8 extend-
ed-spectrum -lactams were collected. Participating laboratories used their own routine susceptibility testing
procedures (88% automatic systems, 10% disk diffusion, and 2% agar dilution). Control results were estab-
lished by two independent reference laboratories by applying the NCCLS microdilution method and interpre-
tative criteria. Interpretative discrepancies were observed in 16% of the results (4.4% for cefepime, 3.0% for
aztreonam, 2.8% for piperacillin-tazobactam, 1.7% for cefotaxime [CTX] and ceftazidime, 1.1% for ceftriaxone,
0.9% for meropenem, and 0.3% for imipenem). High consistency with reference values (<5% of major plus very
major errors) was observed with (i) American Type Culture Collection quality control strains; (ii) strains with
low-efficiency mechanisms inactivating extended-spectrum -lactams, such as OXA-1-producing Escherichia-
coli or SHV-1-hyperproducing Klebsiella pneumoniae; (iii) strains with highly efficient mechanisms, such as
SHV-5 porin-deficient K. pneumoniae, CTX-M-10 in Enterobacter cloacae hyperproducing AmpC, and P. aerugi-
nosa with the MexAB OprM efflux phenotype or hyperproducing AmpC. Low consistency (>30% major plus
very major errors) was detected in K1-producing Klebsiella oxytoca, CTX-M-9-producing E. coli, and in OprD
P. aeruginosa strains. Extended-spectrum -lactamase (ESBL)-producing strains accounted for 86% of very
major errors. Recognition of the ESBL phenotype was particularly low in Enterobacter cloacae strains (<35%),
due to the lack of NCCLS-specific rules in this genus. A K1-producing K. oxytoca was misidentified by 10% of
laboratories as an ESBL producer. The use of well-defined resistant strains is useful for improving proficiency
in susceptibility testing in clinical laboratories.
Antimicrobial susceptibility testing is one of the most im-
portant tasks of clinical microbiology laboratories (11). It is
performed daily in clinical laboratories by standardized meth-
ods. The disk diffusion technique has been extensively used for
this objective; however, semiautomated or automated systems
based on microdilution techniques are replacing this method,
at least for nonfastidious organisms (9).
Quality assurance of antimicrobial susceptibility testing is
commonly performed by using internal quality control proto-
cols, which monitor the precision and accuracy of the method,
the performance of the reagents, and the performance of the
microbiologist or technicians carrying out these procedures
(14). These protocols often use organisms susceptible to the
majority of antimicrobial agents (24) and, to a lesser extent,
resistant strains (36). Additional external quality control as-
sessments (proficiency testing) are necessary in the quality
assurance of antimicrobial susceptibility testing methods (2).
In this case, organisms with susceptibility defined by reference
methods are distributed as unknown strains from a central
laboratory to participating laboratories. This approach has
been used to compare susceptibility testing results among dif-
ferent laboratories or to demonstrate their ability to detect
resistant organisms, both locally and at a national level (1, 31,
32).
In the present study, we performed a multicenter study in
Spain on the proficiency of broad-spectrum -lactam suscep-
tibility testing of a well-defined collection of Enterobacteriaceae
and Pseudomonas aeruginosa strains. Strains were carefully
selected on the basis of resistance phenotypes to these -lac-
tam antibiotics. Moreover, the ability of Spanish laboratories
to detect 6 extended-spectrum -lactamase (ESBL)-producing
Enterobacteriaceae, including two ESBL-producing Enterobac-
ter cloacae strains, was also evaluated.
(This work was presented in part at the 41st Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, Ill., 16 to 19 December 2001.)
MATERIALS AND METHODS
Bacterial strains and participating laboratories. Thirteen Enterobacteriaceae
and 5 P. aeruginosa strains, coded as strains 1 through 18, were selected from the
strain collections of Ramón y Cajal (Madrid, Spain) and Virgen Macarena
(Seville, Spain) University Hospitals (Table 1). This batch included 16 strains
(strains 2 to 13 and 15 to 18) with different resistance mechanisms, which variably
affect broad-spectrum -lactam antimicrobials, and two reference quality control
strains recommended by the NCCLS (strains 1 and 14) (24). Isolates were
inoculated onto nutrient agar slants, incubated overnight, and distributed to 52
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participating Spanish clinical laboratories. Slants were labeled with the number
of the strain (1 through 18) and the bacterial species name (i.e., Escherichia coli
or Klebsiella oxytoca), blinding the susceptibility pattern or the identified resis-
tance mechanisms. Instructions to the participating laboratories indicated that
organisms would be studied for antimicrobial susceptibility testing by the routine
method in each laboratory. A report form was provided to fill in quantitative
(zone diameters or MICs) and qualitative (susceptible, intermediate, or resis-
tant) results for eight broad-spectrum -lactam antibiotics (piperacillin-tazobac-
tam, ceftriaxone, cefotaxime, ceftazidime, cefepime, meropenem, and imipen-
em). The form also included a questionnaire to provide hospital (number of
beds) and laboratory information (routine test method for susceptibility testing,
interpretive criteria, and organization of antimicrobial susceptibility testing).
Laboratories were encouraged to provide the susceptibility testing results with
the interpretation (susceptible, intermediate, or resistant) reported to the clini-
cians and also to include corrections performed after detecting resistance mech-
anisms (i.e., detection of an ESBL in E. coli and correction of apparently sus-
ceptible cephalosporin MICs). Both reference laboratories checked the stability
of resistance mechanisms in the tested strains by serial passage and exchanged
the studied strains twice.
Characterization of resistance mechanisms. Most of these resistant strains
have been published elsewhere (see references in Table 1). Resistance mecha-
nisms characterization included -lactamase (isoelectric focusing, specific enzy-
matic activity, substrate profile determinations, PCR, and sequencing) and outer
membrane profile studies. The efflux resistance mechanism was inferred in P. aeru-
ginosa on the basis of resistance phenotype and on identification of OprM by
Western blotting (kindly performed by N. Gotoh, Kyoto, Japan).
Reference antimicrobial susceptibilities and interpretation of results. The
antimicrobial susceptibility profiles (reference values) of the bacterial strains
were studied by the NCCLS (20) broth microdilution and disk diffusion methods
(25, 26) at the Ramón y Cajal and Virgen Macarena University Hospitals.
Cefoxitin MICs were also determined for E. coli and Klebsiella pneumoniae
isolates in order to facilitate phenotypic analysis of resistance. Isolates were
defined as susceptible, intermediate, or resistant by using the NCCLS criteria
(24). Identifications were also confirmed at these institutions by using the API
strip (bioMerieux, Marcy l’Etoile, France) and standard biochemical test when
necessary (23).
MICs, zone sizes, and interpretative results from participating laboratories
were compared with reference values. Interpretative discrepancies were classi-
fied as very major, major, or minor errors. Very major errors occurred when the
results obtained by the participant were in the susceptible category, whereas they
were in the resistant category with the reference method; the number of suscep-
tibility testing determinations with the reference resistant interpretation result
was used as the denominator (8). Conversely, major errors occurred when the
results obtained by the participant were in the resistant category, whereas they
were in the susceptible category with the reference method; the number of
susceptibility testing determinations with the reference susceptible interpretation
result was used as the denominator (8). Finally, minor errors occurred when the
results obtained by the participant were susceptible or resistant and intermediate
by the reference method or when the results obtained by the participant were
intermediate and susceptible or resistant by the reference method.
RESULTS
Participating hospital methods and interpretive criteria.
Eighty-eight percent of participating laboratories used auto-
matic systems for routine susceptibility testing: 19 laboratories
used the Combo 1S microdilution panels with MicroScan
WalkAway (18 laboratories) or AutoScan (1 laboratory) sys-
tems (Dade MicroScan, Inc., West Sacramento, Calif.); 13
laboratories used the Wider system, a computer-assisted im-
age-processing device adapted to read and interpret microdi-
lution panels (5), with 6- and 5-W microdilution panels (Fran-
cisco Soria Melguizo, Madrid, Spain); 7 laboratories used the
VITEK system with the GNS-518 and GNS-519 cards for En-
terobacteriaceae and P. aeruginosa, respectively (bioMèrieux); 5
laboratories used the VITEK2 system with AST-N010 and
AST-N011 cards for Enterobacteriaceae and P. aeruginosa, re-
spectively (bioMèrieux); and 2 laboratories used Sensititre
with EMIZA8EF panels (Trek Diagnostic Systems, Westlake,
Ohio). Ten percent (5 laboratories) used the disk diffusion
technique, and 2% (1 laboratory) used the agar dilution tech-
nique. All participating laboratories interpreted susceptibility
testing results by following the NCCLS criteria (24), but 15%
performed corrections according to the Spanish Antibiogram
Committee (Mesa Española para la Normalización de la Sen-
sibilidad y Resistencia a los Antimicrobianos [MENSURA]
group) (21). In our study, the MENSURA corrections ex-
tended the NCCLS interpretive categorization for cephalospo-
rins and aztreonam in ESBL-producing E. coli and Klebsiella
spp. to other Enterobacteriaceae isolates.
Proficiency results. The reference broth microdilution MICs
of piperacillin-tazobactam, ceftriaxone, cefotaxime, ceftazi-
dime, cefepime, meropenem, and imipenem for the study
strains are shown in Table 2. Reference interpretative catego-
ries were those obtained after applying the NCCLS guidelines
(24) (Table 2). The distribution of interpretative discrepancies
and categorical error rates by organisms and antibiotics are
TABLE 1. Characteristics of study strains
Strain Characteristic(s) Reference
E. coli ATCC 25922 NCCLS quality control strain 24
E. coli HUS 31-94 Hyperproduction of AmpC -lactamase plus impermeability (OmpF) 19
K. pneumoniae JCH1 Hyperproduction of SHV-1 -lactamase 6
E. coli RYC9765550 OXA-1 -lactamase 27
E. coli RYC5H/9 TEM-27 ESBL plus TEM-1 -lactamase 22
E. coli RYC97056888 CTX-M-9 ESBL plus TEM-1 -lactamase Coque et al.a
K. oxytoca RYC9147/8 K1 -lactamase 36
K. pneumoniae LB3 SHV-5 ESBL plus impermeability (OmpK35) 20
K. pneumoniae LB4 SHV-5 ESBL plus impermeability (OmpK35 and OmpK36) 20
E. cloacae RYC11439/9 I AmpC -lactamase 36
E. cloacae RYC11439/9 SDM Hyperproduction of AmpC -lactamase 36
E. cloacae RYC97095983 I AmpC -lactamase plus CTX-M-10 ESBL 4
E. cloacae RYC97095983 SDM Hyperproduction of AmpC plus CTX-M-10 ESBL This study
P. aeruginosa ATCC 27853 NCCLS quality control strain 24
P. aeruginosa HUS C28 Hyperproduction of AmpC -lactamase 13
P. aeruginosa PAO1 OprD AmpC -lactamase plus impermeability (OprD) 35
P. aeruginosa HUS3 MUT3 Hyperproduction of AmpC plus impermeability (OprD) 18
P. aeruginosa HUSC9 AmpC -lactamases plus hyperproduction of OprM (MexAB OprM) 13
a T. M. Coque, M. C. Varela, A. Oliver, M. I. Morosini, F. Baquero, and R. Cantón, 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. C2-298, 2001.
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shown in Tables 3 and 4, respectively. Only interpretative re-
sults were used for further analysis of the proficiency results.
Quantitative susceptibility values were not considered to be
different; automatic systems use different range concentrations
of tested antibiotics, which makes further comparison impos-
sible. For instance, the Wider system users employ panels
(reference, 5 W) which include 8 concentrations of ceftriaxone
(range, 0.12 to 16 g/ml), whereas some MicroScan users em-
ploy panels (reference, Combo breakpoint gram-negative 1S)
which only include 2 concentrations of the same antibiotic (8
and 32 g/ml). As a result of the exclusion of MICs, zone sizes
were also not used in the analysis and only interpretative cat-
egories were considered. With these criteria, high consistency,
less than 5% of major plus very major (MVM) discrepancies,
was found for E. coli ATCC 25922 and E. coli with OXA-1
-lactamase, K. pneumoniae with SHV-1 -lactamase, K. pneu-
moniae with SHV-5 ESBL and porin OmpK35 and OmpK36
deficiency, E. cloacae hyperproducing AmpC plus CTX-M-10
ESBL, P. aeruginosa ATCC 27853, P. aeruginosa hyperproduc-
ing AmpC, and a P. aeruginosa strain with the efflux phenotype
(MexAB OprM). An MVM rate between 5 and 10% was found
in AmpC-hyperproducing E. coli, AmpC-inducible E. cloacae,
and a P. aeruginosa strain deficient in porin OprD. Strains
with an MVM rate higher than 10% but lower that 20% were
SHV-5 ESBL-producing K. pneumoniae and a porin OmpK35-
deficient and AmpC-hyperproducing E. cloacae strain, where-
as strains with an MVM rate higher than 20% and lower
than 30% were E. coli with TEM-27 ESBL and E. cloacae
with CTX-M-10. The highest discrepancy was detected (an
MVM rate higher than 30% and lower than 40%) in E. coli
with CTX-M-9 ESBL, K1 -lactamase-producing K. oxytoca,
and the AmpC-hyperproducing P. aeruginosa porin-deficient
(OprD) strain.
It is worth noting that 86% of very major errors were ob-
served in ESBL strains, particularly with TEM-27 and CTX-
M-9 ESBL-producing strains (Table 3). The highest major
error rates were observed with the AmpC-hyperproducing plus
porin-deficient (OprD) P. aeruginosa (25.5%) and the K1
-lactamase-producing K. oxytoca (22.5%) strains (Table 3). In
the former, these results were mainly (75%) due to cefepime
and meropenem, and in the latter, these results were due to
ceftriaxone, cefepime, and aztreonam interpretive values.
Moreover, this P. aeruginosa strain (strain 17) had the highest
rate of minor errors (27.1%).
The analysis of interpretative discrepancies by antibiotics
revealed that cefepime had the highest rate, 30.5%, when con-
sidering the number of susceptibility testing determinations for
TABLE 2. Reference susceptibility testing result and interpretive category according to NCCLS criteriaa
Strain Characteristic(s)
MIC (g/ml) of b:
P/T FOX CTX CRO CAZ FEP ATM IMP MER
E. coli ATCC 25922 ATCC QC 2/4 (S) 2 (S) 0.06 (S) 0.06 (S) 0.25 (S) 0.03 (S) 0.12 (S) 0.12 (S) 0.01 (S)
E. coli HUS 31-94 AmpC 1c  OmpF 64/4 (I) 256 (R) 16 (I) 16 (I) 256 (R) 1 (S) 32 (R) 0.25 (S) 0.01 (S)
K. pneumoniae JCH1 SHV-1 1 16/4 (S) 2 (S) 0.25 (S) 0.25 (S) 1 (S) 0.12 (S) 0.25 (S) 0.06 (S) 0.01 (S)
E. coli RYC9765550 OXA-1 32/4 (I) 2 (S) 0.25 (S) 0.12 (S) 0.5 (S) 1 (S) 0.12 (S) 0.12 (S) 0.01 (S)
E. coli RYC5H/9 TEM-27  TEM-1 1/4 (S) 2 (S) 0.5 (R) 0.5 (R) 512 (R) 1 (R) 256 (R) 0.12 (S) 0.01 (S)
E. coli RYC97056888 CTX-M-9  TEM-1 1/4 (S) 2 (S) 8 (R) 16 (R) 0.5 (R) 4 (R) 1 (R) 0.06 (S) 0.01 (S)
K. oxytoca RYC9147/8 K1 128/4 (R) 2 (S) 0.12 (S) 1 (S) 0.12 (S) 0.06 (S) 4 (S) 0.06 (S) 0.01 (S)
K. pneumoniae LB3 SHV-5  OmpK35 8/4 (S) 2 (S) 8 (R) 4 (R) 128 (R) 1 (R) 128 (R) 0.06 (S) 0.01 (S)
K. pneumoniae LB4 SHV-5  Omp35/36 512/4 (R) 64 (R) 128 (R) 64 (R) 512 (R) 32 (R) 512 (R) 0.12 (S) 0.06 (S)
E. cloacae RYC11439/9 I AmpC 1/4 (S) NA 0.25 (S) 0.25 (S) 0.25 (S) 0.06 (S) 0.06 (S) 0.12 (S) 0.03 (S)
E. cloacae RYC11439/9 SDM AmpC 1 256/4 (R) NA 256 (R) 256 (R) 256 (R) 4 (S) 128 (R) 0.12 (S) 0.06 (S)
E. cloacae RYC97095983 I AmpC  CTX-M-10 1/4 (S) NA 64 (R) 64 (R) 2 (S)d 8 (S)d 16 (I)d 0.12 (S) 0.03 (S)
E. cloacae RYC97095983 SDM AmpC 1  CTX-M-10 64/4 (I) NA 256 (R) 256 (R) 64 (R) 32 (R) 64 (R) 0.12 (S) 0.06 (S)
P. aeruginosa ATCC 27853 ATCC QC 2/4 (S) NA NA NA 2 (S) 2 (S) 4 (S) 2 (S) 0.25 (S)
P. aeruginosa HUS C28 AmpC 1 256/4 (R) NA NA NA 256 (R) 16 (1) 64 (R) 1 (S) 0.25 (S)
P. aeruginosa PAO1 OprD- AmpC  OprD 1/4 (S) NA NA NA 1 (S) 1 (S) 2 (S) 16 (R) 2 (S)
P. aeruginosa HUS3 MUT3 AmpC 1  OprD 512/4 (R) NA NA NA 32 (R) 8 (S) 16 (I) 16 (R) 4 (S)
P. aeruginosa HUSC9 AmpC  MexABOprM 8/4 (S) NA NA NA 32 (R) 8 (S) 16 (I) 2 (S) 4 (S)
a NCCLS interpretive criteria are given in reference 24.
b P/T, piperacillin-tazobactam; CTX, cefotaxime; CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MER, meropenem; S,
susceptible; I, intermediate; R, resistant; NA, not applicable.
c1, hyperproduction.
d The presence of an ESBL in these isolates led reference laboratories to consider cephalosporins and aztreonam as resistant; however, interpretation of results has
been performed considering the indicated interpretive categories according to NCCLS criteria (24).
TABLE 3. Distribution of interpretive discrepancies and categorical












% of errors of type
Minora Majorb Verymajorc
Piperacillin-tazobactam 809 21.2 13.9 9.1 7.7
Ceftriaxone 352 19.6 10.8 15.6 5.2
Cefotaxime 647 17.0 10.2 6.4 8.0
Ceftazidime 892 11.8 4.8 8.9 5.1
Cefepime 903 30.5 13.9 16.9 19.3
Aztreonam 848 22.1 13.9 13.6 6.6
Imipenem 919 2.4 1.6 0.6 1.9
Meropenem 829 6.6 3.6 3.0 0
Total 6,199 15.9d 8.8d 7.6 7.8
a Considering the number of susceptibility testing determinations for each
antibiotic as the denominator.
b Considering the number of susceptible strains for each antibiotic as the
denominator.
c Considering the number of resistant strains for each antibiotic as the denom-
inator.
d Considering the total number of susceptibility testing determinations as the
denominator.
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this antibiotic and a rate of 4.4%, when considering the total
number of susceptibility testing determinations, followed by
piperacillin-tazobactam (21.2 and 2.8%), aztreonam (22.1
and 3.0%), ceftriaxone (19.6 and 1.1%), cefotaxime (17.0 and
1.7%), ceftazidime (11.8 and 1.7%), meropenem (6.6 and
0.9%), and imipenem (2.4 and 0.3%).
Cefepime was also the tested antimicrobial with the highest
very major (19.3%) and major (16.9%) error rates. In this
antibiotic, all very major, 22% of major, and 25% of minor
errors were concentrated on ESBL-producing Enterobacteri-
aceae. Moreover, cefepime minor errors were mainly observed
with P. aeruginosa strains (69%).
In general, carbapenem discrepancies were low and were
mainly concentrated in P. aeruginosa strains with a porin defi-
ciency (OprD) or expressing MexAB OprM: strains 16 (20%
of carbapenem discrepancies), 17 (43% of carbapenem dis-
crepancies), and 18 (26% of carbapenem discrepancies).
ESBL recognition and misidentification of non-ESBL pro-
ducers as ESBL producers. Not all laboratories studied all
cephalosporins on ESBL-producing strains, which may have
affected their ability to recognize ESBL. Two laboratories did
not study cefotaxime, ceftazidime, and cefepime in ESBL-
producing E. coli or K. pneumoniae strains (strains 5, 6, 8, and
9), and three laboratories did not study these antibiotics in
ESBL-producing E. cloacae strains (strains 12 and 13). In all
these strains, ceftriaxone and aztreonam were less frequently
reported (Table 5).
The highest rates of ESBL recognition were obtained with
the SHV-5-producing and OmpK35-lacking K. pneumoniae
(strain 8) (71.1%) and the TEM-27-producing E. coli (strain 5)
(69.2%), for which the ceftazidime was highly affected. This
fact can be related with the study of the ceftazidime-clavu-
lanate combination in 67.3% of participating laboratories (data
not shown). The CTX-M-9-producing E. coli (strain 6) was
recognized as an ESBL producer by 61.5% of participating
laboratories, decreasing to 40.4% in the case of the SHV-5-
producing K. pneumoniae lacking the OmpK35 and OmpK36
porins (strain 9). ESBL was less frequently recognized in
E. cloacae strains (34.6 and 9.6%), probably due to the lack of
NCCLS-specific recommendations for screening and confirma-
tion of ESBL in this genus (24) and difficulties in discriminat-
ing between the ESBL phenotype and that of the AmpC-
hyperproducing phenotype (37).
With the exception of VITEK2, which uses an algorithm to
recognize ESBL-producing strains, the other automatic sys-
tems used by participating laboratories include the ceftazi-
dime-clavulanate combination for this purpose. In addition, 30
laboratories (57%) also used the double-disk synergy test (25
laboratories) and/or specific E-test (8 laboratories) as ESBL
confirmatory tests (7, 10). Misidentification of the K1 -lacta-
mase-producing K. oxytoca strain (strain 7) as an ESBL pro-
ducer occurred in five laboratories (10%), all of them using the
double-disk synergy confirmatory test for ESBL. Moreover,
three laboratories (6%) misidentified the AmpC-hyperproduc-
ing E. coli strain (strain 2) as an ESBL producer, two of them
using the ceftazidime-clavulanate confirmatory E-test for ESBL.
DISCUSSION
Different multicenter studies have been performed to study
the ability of laboratories to detect specific resistance mecha-






E. coli ATCC 25922 ATCC QC 0.3 1.1 0
E. coli HUS 31-94 AmpC 1  OmpF 23.7 6.2 0
K. pneumoniae JCH1 SHV-1 1 1.6 0.8 0
E. coli RYC9765550 OXA-1 8.9 5.0 0
E. coli RYC5H/9 TEM-27  TEM-1 4.4 4.9 17.3
E. coli RYC97056888 CTX-M-9  TEM-1 4.6 3.6 29.9
K. oxytoca RYC9147/8 K1 6.3 22.5 17.7
K. pneumoniae LB3 SHV-5  OmpK35 6.8 5.6 8.9
K. pneumoniae LB4 SHV-5  OmpK35/36 3.0 0 3.3
E. cloacae RYC11439/9 I AmpC 2.2 7.5 0
E. cloacae RYC11439/9 SDM AmpC 1 3.3 13.0 2.3
E. cloacae RYC97095983 I AmpC  CTX-M-10 10.7 20.9 1.3
E. cloacae RYC97095983 SDM AmpC 1  CTX-M-10 8.1 0 4.2
P. aeruginosa ATCC 27853 ATCC QC 3.3 3.6 0
P. aeruginosa HUS C28 AmpC 1 17.3 1.1 0
P. aeruginosa PAO1 OprD AmpC  OprD 3.7 5.0 3.8
P. aeruginosa HUS3 MUT3 AmpC 1  OprD 27.1 25.5 4.6
P. aeruginosa HUSC9 AmpC  MexABOprM 2.3 4.9 0
a1, hyperproduction.
TABLE 5. ESBL-producing isolates and interpretive susceptibility results of cephalosporins and aztreonam
reported by participating laboratoriesa
Strain Characteristic(s)b































S I R S I R S I R S I R S I R
E. coli RYC5H/99 TEM-27  TEM-1 0.5 16 3 31 0.5 8 4 16 512 0 0 50 1 14 4 32 256 1 4 42
E. coli RYC97056888 CTX-M-9  TEM-1 8 3 2 45 16 0 4 22 0.5 23 1 26 4 13 6 31 1 20 2 26
K. pneumoniae LB3 SHV-5  OprK35 8 5 4 41 4 2 6 19 128 0 2 48 1 11 5 34 128 1 0 46
K. pneumoniae LB4 SHV-5  OmpK35/36 128 1 2 47 64 0 2 25 512 1 0 49 32 4 3 43 512 1 0 45
E. cloacae RYC97095983 I AmpC  CTX-M-10 64 1 7 41 64 0 2 26 2 24 7 18 16 17 9 23 8 11 13 22
E. cloacae RYC97095983 SDM AmpC 1  CTX-M-10 256 1 0 48 256 0 0 27 64 1 0 48 32 6 5 38 64 1 0 45
a Ref, reference; S, susceptible; I, intermediate; R, resistant. MICs are given in micrograms per milliliter.
b1, hyperproduction.
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nisms that, when present in infectious pathogens, represent a
clinical concern (1, 30, 33). Most of these studies have been
designed as proficiency quality control studies, distributing re-
sistant strains from a central laboratory, which normally acts as
a reference laboratory, to different participating laboratories.
We present the results of a Spanish multicenter study on the
proficiency of broad-spectrum -lactam susceptibility testing of
a well-defined collection of Enterobacteriaceae and P. aerugi-
nosa strains. Strains were carefully selected on the basis of
resistance phenotypes to these -lactam antibiotics. The resis-
tance mechanisms, which included ESBLs, AmpC -lactamase
hyperproduction, permeability defect, and/or efflux-based
mechanisms, represent a major challenge to these broad-spec-
trum antimicrobials (3, 15, 33). Moreover, we considered eight
broad-spectrum antimicrobials belonging to different -lactam
groups (cephalosporins, monobactams, carbapenem, and -
lactam and -lactamase-inhibitor combinations), which were
variably affected by these resistance mechanisms (Table 1).
It has been assumed that detection and recognition of the
aforementioned resistance mechanisms may be difficult for
clinical laboratories when routinely testing organisms, partic-
ularly with automated systems (29, 33). Some of these prob-
lems may be related to the limit of antibiotics and antibiotic
concentrations included in the susceptibility testing panels,
which affect the ability of laboratories to detect the resistance
phenotypes (30, 32). Moreover, susceptibility testing of ESBL-
and AmpC-producing organisms may produce inconsistent
or anomalous quantitative results (12, 16, 33), which can
also affect interpretative (qualitative) results. This issue be-
comes even more complex when more than one resistance
mechanism is present in a single isolate due to a superimposed
resistance phenotype. The lack of appropriate reporting con-
ventions enhances difficulties for the accurate interpretation of
susceptibility testing results, affecting the appropriate selection
of antimicrobial therapy (3, 33).
In our study, well-characterized resistant strains were useful
in demonstrating the proficiency of routine susceptibility test-
ing. In addition, our aim was to detect which -lactam antimi-
crobial susceptibility testing had the highest difficulties and for
which strains (or the resistance mechanism) difficulties were
higher. Neither of the NCCLS recommended quality control
strains, E. coli ATCC 25922 and P. aeruginosa ATCC 27853,
represented problems in susceptibility testing. Only 0.3 and
1.1% of minor and major errors, respectively, were observed in
the former and 3.3 and 3.6%, respectively, in the latter, denot-
ing the high quality of performance of routine susceptibility
testing in Spain. This situation was similar with strains express-
ing resistance mechanisms which slightly affect the studied
-lactams but for which MIC or inhibition zone values fall in
the susceptible category (i.e., OXA-1-producing E. coli or
SHV-1-hyperproducing K. pneumoniae strains). This was also
the case for those strains expressing resistance mechanisms,
which unlike the former, highly affect cephalosporins (i.e.,
SHV-5-producing K. pneumoniae deficient in both OmpK35
and OmpK36 porins, E. cloacae hyperproducing AmpC plus
CTX-M-10 ESBL, P. aeruginosa hyperproducing AmpC, and a
P. aeruginosa strain with the MexAB OprM efflux phenotype).
On the contrary, the highest combined MVM discrepancies
(20%) were detected in K1-producing K. oxytoca, E. cloacae
with CTX-M-10 ESBL, E. coli with TEM-27 or CTX-M-9, and
an OprD AmpC-hyperproducing P. aeruginosa strain. It is
worth noting that this group included two E. coli strains with a
clear ESBL phenotype, the TEM-27 and CTX-M-9 producers.
The TEM-27 enzyme highly affects ceftazidime but not cefo-
taxime or ceftriaxone, whereas the CTX-M-9 enzyme does not
apparently affect ceftazidime (Table 2). In both strains, as well
as in other ESBL producers, cefepime was slightly affected, but
a high inoculum size effect for this antibiotic was noted (27,
34), which was partially responsible for these discrepancies. In
addition, the inability of some participating laboratories to
realize that an ESBL was present in some of these strains was
also responsible for the high rate of cefepime-interpretative
discrepancies (30.5%). Moreover, all cefepime very major
errors (19.3%) were observed in ESBL-producing strains.
Although the ability of cefepime to be active against ESBL-
producing organisms is controversial (28), in these labora-
tories, cefepime was reported as susceptible and no cate-
gorical modification was performed. This modification is
recommended both in the NCCLS and MENSURA criteria
(21, 24).
Aztreonam (22.1%) and piperacillin-tazobactam (21.2%)
discrepancies were also high, followed by those of ceftriaxone
(19.6%), cefotaxime (17.0%), and ceftazidime (11.8%). All of
these antibiotics were variably affected by the resistance mech-
anisms. This was not the case with imipenem and meropenem,
which were the antibiotics least affected by the resistance
mechanisms and those for which lower interpretative discrep-
ancies, 2.4 and 6.6%, respectively, were observed.
The detection of ESBL was also specifically studied in our
multicenter study. In general, the ability of the Spanish labo-
ratories to detect the presence of ESBL-producing isolates and
consequently to modify susceptibility testing reports was higher
than that observed in other studies (30–32). This fact can be
related with the high number of laboratories using automatic
susceptibility testing devices incorporating the so-called expert
software that helps the microbiologist interpret phenotypes (9,
16) and, in addition, that nearly 60% of laboratories routinely
made phenotypic verification of ESBL producers by using con-
firmatory tests.
In a multicenter study performed among users of the
WHONET software during a 3-year period (1996 through
1999), only 1.5% of laboratories reported that a TEM-3 ESBL-
producing K. pneumoniae was specifically an ESBL isolate
(31). In this study, although 88% of laboratories reported that
the K. pneumoniae isolate was resistant to at least one extend-
ed-spectrum cephalosporin, none of them modified the inter-
pretation of the other cephalosporins to resistant, as currently
suggested by the NCCLS. Moreover, in a study performed in
1998 in Connecticut, 18.4% of 38 participating laboratories
noted on their report forms that at least one of the five organ-
isms used in the study (only three contained an ESBL) con-
tained a presumptive ESBL. In addition, 21.0% of these lab-
oratories failed to detect extended-spectrum cephalosporin or
aztreonam resistance in any of the ESBL- or AmpC-producing
isolates (32).
In our study, 71% of participating laboratories were able to
infer the presence of an ESBL in the K. pneumoniae SHV-5-
producing strain. This strain had the typical ESBL resistance
profile and produced the typical synergy between ceftazidime
and clavulanate included in most of the automated systems
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(Wider, VITEK, and MicroScan). The ability of participating
laboratories was also high in the TEM-27 ESBL-producing
E. coli strain (69.2%), which also showed this typical synergy
effect. It is also of interest that 61.5% of laboratories were able
to infer the presence of an ESBL in the CTX-M-9-producing
isolate, which did not produce this typical ceftazidime-clavu-
lanate synergy. Conversely, as shown by both reference labo-
ratories and participating laboratories performing the ESBL
confirmatory disk approximation test, this strain showed a
clear cefotaxime-clavulanate synergy. Unfortunately, this com-
bination was not present in the automated systems used for
susceptibility testing, which would have enhanced the ability to
detect the CTX-M-9-producing E. coli strain.
The ability to detect an ESBL was dramatically decreased in
the CTX-M-10-producing E. cloacae strain (34.6%) and par-
ticularly in the isogenic AmpC-hyperproducing isolate (9.6%).
In both strains, the ESBL phenotype may be confused with the
overexpressed AmpC phenotype. In addition, ceftazidime-cla-
vulanate synergy was not clear due to the CTX-M ESBL pro-
duction, which may interfere with ESBL detection (4, 37). In
both strains, a low rate of susceptibility testing report modifi-
cation was also performed, which was undoubtedly related to
the fact that the NCCLS only recommended rules for ESBL-
producing E. coli and Klebsiella spp. but not for ESBL-produc-
ing Enterobacter or other AmpC-producing isolates (24). Those
laboratories using the NCCLS recommendations modified
with the MENSURA criteria (21) performed susceptibility
testing report modifications in ESBL AmpC-producing strains.
In our opinion, the NCCLS should also include screening and
confirmatory tests for ESBL not only in E. coli, K. pneumoniae,
and K. oyxtoca but also in other Enterobacteriaceae organisms.
Misidentification of a non-ESBL producer as an ESBL pro-
ducer has been previously reported (30). Most of these misi-
dentifications are due to the presence of clavulanate-inhibited
-lactamases that slightly affect expanded-spectrum cephalo-
sporins (i.e., the K1 enzyme in K. oxytoca), which may offer
synergy results in some confirmatory tests for ESBL (i.e., K1
enzyme-producing K. oxytoca in the disk approximation test
among aztreonam, ceftriaxone, and/or cefotaxime with amoxi-
cillin-clavulanate) (unpublished results). In our study, five
(10%) participating laboratories using the double-disk synergy
confirmatory test for ESBL misidentified a K1 -lactamase-
producing K. oxytoca as an ESBL-producing strain and made
interpretative modifications in all cephalosporins tested and
aztreonam and not only in those affected to a higher extent
(ceftriaxone or aztreonam). These modifications are a matter
of discussion (17), as no clear criteria have been published. In
our study, reference values for this K. oxytoca strain were those
corresponding to the strict NCCLS interpretation of the inhi-
bition zone or MICs. Furthermore, three participating labora-
tories (6%) misidentified an AmpC-hyperproducing E. coli
strain as an ESBL producer. This also occurred in a previous
study including an AmpC-hyperproducing strain in a batch of
5 strains containing three ESBL-producing strains when no
laboratory differentiated the AmpC-producing strain from the
other ESBL-producing strains (31). It should be noted that in
our study, all misidentification in the K. oxytoca and E. coli
strains occurred in automatic susceptibility testing system users
but not in disk diffusion users (data not shown in tables).
In summary, our study demonstrated that well-defined re-
sistant strains were useful for the study of susceptibility testing
proficiency at the national level. For broad-spectrum -lactam
antibiotics, antimicrobial susceptibility testing had the highest
difficulties for those strains with -lactam-resistant mecha-
nisms yielding complex phenotypes, the most affected antimi-
crobials being cefepime, aztreonam, and piperacillin-tazobac-
tam. Moreover, the detection of ESBL-producing strains was
more difficult in those strains for which ESBL are atypical (E.
cloacae) or when superimposed with other resistance mecha-
nisms (ESBL K. pneumoniae with porin deficiency). Quality
control exercises performed at the national level are essential
to estimate the sensitivity of the diagnostic microbiological
facilities of the country for the detection of new bacterial
threats and the time to react to them. Extensive information
has been provided now to the participating laboratories. We
hope that this initiative will improve the ability of our diagnos-
tic microbiological laboratories to deal with new threats in
antimicrobial resistance.
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Nuestra Señora de Avilés (Avilés); I. Alamo, Hospital Dr. Negri (Las
Palmas); A. Moreno-Docón. Hospital Ntra. Sra. de la Candelaria (San-
ta Cruz de Tenerife); D. Romero-Aguilera, Hospital de Alarcos
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